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SMethods: We assessed the inﬂuence of diabetes on both short-term (within 30 days)
and long-term (beyond 30 days) bleeding risk after coronary DES implantation.
Accounting for the differences in duration of dual antiplatelet therapy (DAPT)
between diabetic and non-diabetic patients, the Cox proportional hazard model was
used to evaluate long-term bleeding risk treating DAPT as a time-dependent
covariate.
Results: Among consecutive 15939 patients undergoing ﬁrst coronary revasculari-
zation from 2005 to 2007 in the CREDO-Kyoto PCI/CABG registry cohort-2
enrolling patients, we identiﬁed 2807 diabetic patients and 3981 non-diabetic patients
who received at least one drug-eluting stent (DES) implantation. 5-year incidence of
severe bleeding was 5.7% in diabetic patients and 4.1% in non-diabetic patients. No
differences in the rate of bleeding were observed within 30 days (1.0% in diabetic
patients and 1.0% in non-diabetic patients, p¼0.80) (Figure A). Beyond 30 days, the
signiﬁcantly higher cumulative incidence of bleeding among diabetic patients as
compared to non-diabetic patients was observed (Figure B). At multivariate analysis,
adjusted hazard ratio of diabetic patients for long-term severe bleeding was 1.36 (95%
CI: 1.09-1.72, p¼0.01).Conclusions: In comparison with non-diabetic patients, there was a signiﬁcant excess
risk in long-term, but not in short-term, severe bleeding with diabetic patients.
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Background: The Allen test (AT) was described in 1929, by Doctor Edgar V. Allen,
as a method of diagnosing thromboangiitis obliterans. With the advent of radial artery
grafting, surgeons started using this method to assess for adequate hand perfusion,
before harvesting the radial artery. The use of AT for transradial catheterization (TRC)
was recommended as a way to identify those patients that are at risk for the extremely
rare complication of hand ischemia. Currently, there are poor evidence to support
routine use of AT for all patients undergoing TRC . Our aim , is to examine if TRC
can be safely performed without this test.
Methods: We performed a total of 3006 transradial catheterizations between
January 1st, 2006 and December 31st, 2009. Baseline characteristics of our patients
and all procedural information were collected through a computerized database
and close follow up of the current study population was performed until June 2013 .
We evaluated the incidence of asymptomatic radial artery occlusion in patients
undergoing TRC for the ﬁrst time (Group I) and in patients undergoing repeated TRC
(Group II). In both groups we also examined the incidence of symptomatic hand
ischemia.
Results: In total, 2.817 patients (96.9%) underwent a single TRC (Group I) and 91
patients (3.1%) underwent two or more TRC (Group II). While the incidence of
asymptomatic radial artery occlusion raised from 0.1% in Group I to 3.3% in Group II,
there were no cases of symptomatic hand ischemia either on periprocedural or long
term follow up.
Conclusions: More than 3000 catheterizations were performed safely in our center
without the Allen test and that included 91 patients that underwent repeated cathe-
terizations from the same artery without having any signs of hand ischemia. The
incidence of hand ischemia is very rare. Even in the case where radial artery occlusion
occurs, this is mostly asymptomatic due to collateral circulation. Based on our
experience, we conclude that initial or repeated radial artery catheterization can be
safely performed without the Allen test.B94 JACC Vol 62/18/Suppl B j October 27–NovTCT-290
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Background: It is shown that women have less favourable outcomes than men
after percutaneous coronary interventions (PCI) for acute coronary syndrome
(ACS). Difference might be partly attributed to access site and bleeding complica-
tions. Latest scientiﬁc literature report that compared to trans-femoral PCI, showed
trans-radial PCI is associated with lower risk of bleeding and improved clinical
outcomes. We sought to assess potential beneﬁts of trans-radial PCI in female patients
with ACS treated with the Nobori abluminally coated DES with biodegradable
polymer.
Methods: A total of 1426 female patients admitted with ACS have been enrolled in
two large Nobori registries, of which 739 were treated using radial approach (RAD)
and 702 using femoral approach (FEM). The primary endpoint of the study is Target
Lesion Failure (TLF) at 1 year.
Results: The average age (67 years), as well as other baseline characteristics were
similar in both groups. However, patients in RAD group were less likely to have
diabetes (36.6% vs. 42.0%), hypertension (71.6% vs 76.2%) or a previous MI (17.2%
vs 26.8%). Lesion complexity was similar (57.8% vs 63.6% of B2/C type) in RAD
and FEM groups respectively. Procedural success rate was high in both groups (99.3%
RAD vs 98.9% FEM) without signiﬁcant difference. Cross-over from radial to femoral
occurred in 2.1% of the procedures. Major bleeding complications up to 12 months
were numerically lower in RAD patients 0.9% vs 2.4% in FEM patients (p¼0.06). The
patients in the RAD group also showed a clear trend towards a lower number of
adverse events at one year: death RAD 2.0% vs 2.4% in FEM (p¼NS); MI 1.8% vs
2.7% (p¼NS); TVR 2.2% vs 5.0% (p¼0.03), stent thrombosis 0.4% vs 1.4%
(p¼0.04). Cumulative frequency of TLF and MACE was 3.6% and 4.3% in RAD and
3.8% and 5.8% in FEM, respectively.
Conclusions: Favourable clinical outcomes, high procedural success and a low rate of
bleeding complications reported in this study provide additional evidence to support
the use of a radial approach in female patients with ACS whenever such procedures
are technically feasible.TCT-291
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Background: Radial artery occlusion (RAO) remains the "Achilles heel" of trans-
radial coronary procedures. Higher over lower levels of systemic anticoagulation are
believed to reduce RAO rates but this is ill-supported by scientiﬁc evidence.
Methods: This was a prospective, randomized, single-center study of parallel design.
Patients were enrolled if they were older than 18 years old, were scheduled for
diagnostic coronary angiography and the interventional cardiologist was willing to
proceed with either radial or ulnar access. Patients were randomized before diagnostic
catheterization in a 1:1 ratio to receive either 2500 IU or 5000 IU of unfractionated
heparin. Patients were excluded after randomization when crossover to another arterial
access site had been required, a different than 5F sheath size had been inserted or ad
hoc PCI had been performed. Study's primary endpoint was arterial access site
occlusion rate, as conﬁrmed by absence of antegrade ﬂow by Doppler examination,
within 60 days after coronary angiography.
Results: Between June 2010 and January 2013 1167 patients were randomized to
receive either 2500 or 5000 IU of heparin. In total 654 patients were excluded after
randomization, leaving 603 patients (2500 IU N¼302 kai 5000 IU N¼301) to test
study's hypothesis. Patients' baseline and angiographic characteristics (74.5% men,
31.3% diabetics, 38.3% with acute coronary syndrome) were well balanced between
groups. At a median follow-up of 8 (1-60) days (Doppler available in 97.7% of
patients), we observed 60 arterial occlusions among the 589 analyzed patients
(10.2%). However, the occlusion frequency did not differ between the 2500 and 5000
IU Heparin arm (12.0% vs. 8.4%, p¼0.2).
Conclusions: Standard dose of heparin was not found superior to low dose, in
reducing forearm artery occlusion rate after coronary angiography.ember 1, 2013 j TCT Abstracts/POSTER/Vascular Access and Closure
